购物车
- 全部删除
- 您的购物车当前为空
hCAIX-IN-23(Compound 27)是针对人类碳酸酐酶(hCA)IX和XII的新型抑制剂,其Ki值分别为10.4 nM和8.5 nM。该化合物在抑制hCA活性的同时,能够释放NO,兼具抗肿瘤作用。通过调节caspase活性及铁死亡途径(ferroptosis),hCAIX-IN-23促进细胞凋亡(Apoptosis)和降低hCA IX及铁调节蛋白的表达。此化合物主要用于肾癌的研究领域。
hCAIX-IN-23(Compound 27)是针对人类碳酸酐酶(hCA)IX和XII的新型抑制剂,其Ki值分别为10.4 nM和8.5 nM。该化合物在抑制hCA活性的同时,能够释放NO,兼具抗肿瘤作用。通过调节caspase活性及铁死亡途径(ferroptosis),hCAIX-IN-23促进细胞凋亡(Apoptosis)和降低hCA IX及铁调节蛋白的表达。此化合物主要用于肾癌的研究领域。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | hCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 nM for hCA IX and 8.5 nM for hCA XII. It not only inhibits hCA activity but also releases NO, exerting dual anti-tumor effects. By reducing the expression of hCA IX and iron regulatory proteins, hCAIX-IN-23 regulates mitochondrial caspase activity and the ferroptosis pathway, thereby inducing apoptosis. This compound is utilized in research focused on renal cancer. |
靶点活性 | CA IX (human):10.4 nM (Ki), CA XII (human):8.5 nM (Ki) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容